4//SEC Filing
Ali Asif 4
Accession 0001104659-25-024062
CIK 0001377121other
Filed
Mar 13, 8:00 PM ET
Accepted
Mar 14, 6:20 PM ET
Size
13.1 KB
Accession
0001104659-25-024062
Insider Transaction Report
Form 4
Ali Asif
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-12$12.17/sh+15,203$185,021→ 78,024 total - Exercise/Conversion
Common Stock
2025-03-12$19.19/sh+9,700$186,143→ 87,724 total - Exercise/Conversion
Stock Option (right to buy)
2025-03-12−15,203→ 30,547 totalExercise: $12.17Exp: 2033-01-15→ Common Stock (15,203 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-03-12−9,700→ 66,800 totalExercise: $19.19Exp: 2032-04-18→ Common Stock (9,700 underlying) - Sale
Common Stock
2025-03-12$58.73/sh−24,903$1,462,553→ 62,821 total
Footnotes (3)
- [F1]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.12 to $59.235. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F2]The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.
- [F3]The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.
Documents
Issuer
Protagonist Therapeutics, Inc
CIK 0001377121
Entity typeother
Related Parties
1- filerCIK 0001921163
Filing Metadata
- Form type
- 4
- Filed
- Mar 13, 8:00 PM ET
- Accepted
- Mar 14, 6:20 PM ET
- Size
- 13.1 KB